Abstract: The present disclosure relates to in vitro methods of determining the individual HLA patterns (adult and/or embryonic) in body samples (tissue or blood samples) of cancer patients and/or patients suffering disorders related to autoimmune disease and to methods of stratifying said patients for tailored treatments. It further relates to corresponding kits and their uses, as well as to nucleic acid molecules as prognostic biomarkers for neoplastic disease such as cancer, autoimmune disease, infectious disease and conditions related to pregnancy. It also relates to therapeutic agents and to methods of producing therapeutic agents.

Abstract: The invention provides novel compositions, methods and uses, for the diagnosis, prognosis, prediction, prevention and aid in treatment of malignant neoplasia such as breast cancer, ovarian cancer, gastric cancer, colon cancer, esophageal cancer, mesenchymal cancer, bladder cancer or non-small cell lung cancer. Genes that are chromosomally amplified in breast tissue of breast cancer patients are disclosed. Further disclosed are chromosomally amplified genes and non-amplified genes that correlate to Taxane resistance, Taxane benefit or adverse Taxane reaction, which can be used as an aid to make therapy dicisions.